Cargando…
PLAC1 as a serum biomarker for breast cancer
Placental-specific protein 1 (PLAC1) is an X-linked trophoblast gene that is re-expressed in several malignancies, including breast cancer, and is therefore a potential biomarker to follow disease onset and progression. Sera from 117 preoperative/pretreatment breast cancer patients and 51 control su...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809008/ https://www.ncbi.nlm.nih.gov/pubmed/29432428 http://dx.doi.org/10.1371/journal.pone.0192106 |
_version_ | 1783299512706531328 |
---|---|
author | Yuan, Hongyan Chen, Vincent Boisvert, Marc Isaacs, Claudine Glazer, Robert I. |
author_facet | Yuan, Hongyan Chen, Vincent Boisvert, Marc Isaacs, Claudine Glazer, Robert I. |
author_sort | Yuan, Hongyan |
collection | PubMed |
description | Placental-specific protein 1 (PLAC1) is an X-linked trophoblast gene that is re-expressed in several malignancies, including breast cancer, and is therefore a potential biomarker to follow disease onset and progression. Sera from 117 preoperative/pretreatment breast cancer patients and 51 control subjects, including those with fibrocystic disease, were analyzed for the presence of PLAC1 protein as well as its expression by IHC in tumor biopsies in a subset of subjects. Serum PLAC1 levels exceeded the mean plus one standard deviation (mean+SD) of the level in control subjects in 67% of subjects with ductal carcinoma in situ (DCIS), 67% with HER2(+) tumors, 73% with triple-negative cancer and 73% with ER(+)/PR(+) tumors. Greater sensitivity was achieved using the mean+2 SD of control PLAC1 serum values, where the false positive rate was 3% and was exceeded by 38%, 40%, 60% and 43% of subjects with DCIS, HER2(+), TNBC and ER(+)/PR(+)/HER2(-) tumors. PLAC1 was detected in 97% of tumor biopsies, but did not correlate quantitatively with serum levels. There was no significant correlation of serum PLAC1 levels with race, age at diagnosis, body mass index (BMI) or the presence of metastatic disease. It remains to be determined whether PLAC1 serum levels can serve as a diagnostic biomarker for the presence or recurrence of disease post-surgery and/or therapy. |
format | Online Article Text |
id | pubmed-5809008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-58090082018-02-28 PLAC1 as a serum biomarker for breast cancer Yuan, Hongyan Chen, Vincent Boisvert, Marc Isaacs, Claudine Glazer, Robert I. PLoS One Research Article Placental-specific protein 1 (PLAC1) is an X-linked trophoblast gene that is re-expressed in several malignancies, including breast cancer, and is therefore a potential biomarker to follow disease onset and progression. Sera from 117 preoperative/pretreatment breast cancer patients and 51 control subjects, including those with fibrocystic disease, were analyzed for the presence of PLAC1 protein as well as its expression by IHC in tumor biopsies in a subset of subjects. Serum PLAC1 levels exceeded the mean plus one standard deviation (mean+SD) of the level in control subjects in 67% of subjects with ductal carcinoma in situ (DCIS), 67% with HER2(+) tumors, 73% with triple-negative cancer and 73% with ER(+)/PR(+) tumors. Greater sensitivity was achieved using the mean+2 SD of control PLAC1 serum values, where the false positive rate was 3% and was exceeded by 38%, 40%, 60% and 43% of subjects with DCIS, HER2(+), TNBC and ER(+)/PR(+)/HER2(-) tumors. PLAC1 was detected in 97% of tumor biopsies, but did not correlate quantitatively with serum levels. There was no significant correlation of serum PLAC1 levels with race, age at diagnosis, body mass index (BMI) or the presence of metastatic disease. It remains to be determined whether PLAC1 serum levels can serve as a diagnostic biomarker for the presence or recurrence of disease post-surgery and/or therapy. Public Library of Science 2018-02-12 /pmc/articles/PMC5809008/ /pubmed/29432428 http://dx.doi.org/10.1371/journal.pone.0192106 Text en © 2018 Yuan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Yuan, Hongyan Chen, Vincent Boisvert, Marc Isaacs, Claudine Glazer, Robert I. PLAC1 as a serum biomarker for breast cancer |
title | PLAC1 as a serum biomarker for breast cancer |
title_full | PLAC1 as a serum biomarker for breast cancer |
title_fullStr | PLAC1 as a serum biomarker for breast cancer |
title_full_unstemmed | PLAC1 as a serum biomarker for breast cancer |
title_short | PLAC1 as a serum biomarker for breast cancer |
title_sort | plac1 as a serum biomarker for breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809008/ https://www.ncbi.nlm.nih.gov/pubmed/29432428 http://dx.doi.org/10.1371/journal.pone.0192106 |
work_keys_str_mv | AT yuanhongyan plac1asaserumbiomarkerforbreastcancer AT chenvincent plac1asaserumbiomarkerforbreastcancer AT boisvertmarc plac1asaserumbiomarkerforbreastcancer AT isaacsclaudine plac1asaserumbiomarkerforbreastcancer AT glazerroberti plac1asaserumbiomarkerforbreastcancer |